Tuesday, August 13, 2013

An Incomplete List of Cancer Genes that Cause Developmental Syndromes


PROTEUS SYNDROME  AKT1
ANDROGEN INSENSITIVITY SYNDROME; AIS  AR
MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14  ARID1A
MENTAL RETARDATION, AUTOSOMAL DOMINANT 12; MRD12  ARID1B
BOHRING-OPITZ SYNDROME; BOPS  ASXL1
ATAXIA-TELANGIECTASIA; AT  ATM
ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX  ATRX
MICROPHTHALMIA, SYNDROMIC 2; MCOPS2  BCOR
BLOOM SYNDROME; BLM  BLM
CARDIOFACIOCUTANEOUS SYNDROME  BRAF
FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1  BRCA2
FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA  BRIP1
NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC  CBL
BARE LYMPHOCYTE SYNDROME, TYPE II  CIITA
OSTEOGENESIS IMPERFECTA, TYPE I  COL1A1
RUBINSTEIN-TAYBI SYNDROME 1; RSTS1  CREBBP
SUPRAVALVULAR AORTIC STENOSIS; SVAS  ELN
RUBINSTEIN-TAYBI SYNDROME 2; RSTS2  EP300
POTOCKI-SHAFFER SYNDROME  EXT2
WEAVER SYNDROME 2; WVS2  EZH2
FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA  FANCA
FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC  FANCC
FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2  FANCD2
FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE  FANCE
FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF  FANCF
FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG  FANCG
PFEIFFER SYNDROME  FGFR1
HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2  FGFR1
OSTEOGLOPHONIC DYSPLASIA; OGD  FGFR1
TRIGONOCEPHALY 1; TRIGNO1  FGFR1
APERT SYNDROME  FGFR2
PFEIFFER SYNDROME  FGFR2
JACKSON-WEISS SYNDROME; JWS  FGFR2
CROUZON SYNDROME  FGFR2
BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS  FGFR2
LACRIMOAURICULODENTODIGITAL SYNDROME; LADD  FGFR2
ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS;  FGFR2
ACHONDROPLASIA; ACH  FGFR3
THANATOPHORIC DYSPLASIA, TYPE I; TD1  FGFR3
MUENKE SYNDROME; MNKES  FGFR3
CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME  FGFR3
CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN  FGFR3
BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPES  FOXL2
MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND AUTISTIC FEATURES  FOXP1
MCCUNE-ALBRIGHT SYNDROME; MAS  GNAS
SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1  GPC3
RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA; RUSAT  HOXA11
HAND-FOOT-UTERUS SYNDROME  HOXA13
PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS  HOXA13
BRACHYDACTYLY, TYPE D; BDD  HOXD13
BRACHYDACTYLY, TYPE E1; BDE1  HOXD13
SYNPOLYDACTYLY 1; SPD1  HOXD13
SYNDACTYLY, TYPE V  HOXD13
VATER ASSOCIATION  HOXD13
BRACHYDACTYLY-SYNDACTYLY SYNDROME  HOXD13
COSTELLO SYNDROME  HRAS
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ  KDM5C
MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ  KDM5C
KABUKI SYNDROME 2; KABUK2  KDM6A
CARDIOFACIOCUTANEOUS SYNDROME  KRAS
NOONAN SYNDROME 3; NS3  KRAS
STUVE-WIEDEMANN SYNDROME  LIFR
CARDIOFACIOCUTANEOUS SYNDROME  MAP2K1
46,XY SEX REVERSAL 6; SRXY6  MAP3K1
OPITZ-KAVEGGIA SYNDROME; OKS  MED12
LUJAN-FRYNS SYNDROME  MED12
HAIRY ELBOWS, SHORT STATURE, FACIAL DYSMORPHISM, AND DEVELOPMENTAL  MLL
KABUKI SYNDROME 1; KABUK1  MLL2
FEINGOLD SYNDROME 1; FGLDS1  MYCN
AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4  MYH11
NEUROFIBROMATOSIS, TYPE I; NF1  NF1
WATSON SYNDROME  NF1
NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS  NF1
SECKEL SYNDROME 7; SCKL7  NIN
AORTIC VALVE DISEASE 1; AOVD1  NOTCH1
HAJDU-CHENEY SYNDROME; HJCYS  NOTCH2
ALAGILLE SYNDROME 2; ALGS2  NOTCH2
HAJDU-CHENEY SYNDROME; HJCYS  NOTCH2
ALAGILLE SYNDROME 2; ALGS2  NOTCH2
NOONAN SYNDROME 6; NS6  NRAS
SOTOS SYNDROME 1; SOTOS1  NSD1
BECKWITH-WIEDEMANN SYNDROME; BWS  NSD1
WEAVER SYNDROME 1; WVS1  NSD1
INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA  NTRK1
FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA  PALB2
FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN  PALB2
CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS  PAX3
WAARDENBURG SYNDROME, TYPE 3; WS3  PAX3
WAARDENBURG SYNDROME, TYPE 1; WS1  PAX3
CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS  PHOX2B
CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL  PIK3CA
BASAL CELL NEVUS SYNDROME; BCNS  PTCH1
BANNAYAN-RILEY-RUVALCABA SYNDROME; BRRS  PTEN
VACTERL ASSOCIATION WITH HYDROCEPHALUS  PTEN
LEOPARD SYNDROME 1  PTPN11
NOONAN SYNDROME 1; NS1  PTPN11
NOONAN SYNDROME 5; NS5  RAF1
LEOPARD SYNDROME 2  RAF1
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1  RET
CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS  RET
PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY  RUNX1
SHWACHMAN-DIAMOND SYNDROME; SDS  SBDS
PARAGANGLIOMAS 4; PGL4  SDHB
SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME  SETBP1
PULMONARY HYPERTENSION, PRIMARY, 1; PPH1  SMAD4
MENTAL RETARDATION, AUTOSOMAL DOMINANT 16; MRD16  SMARCA4
MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15  SMARCB1
CAMPOMELIC DYSPLASIA  SOX9
46,XX SEX REVERSAL 2; SRXX2  SOX9
NEMALINE MYOPATHY 1; NEM1  TPM3
ACHONDROGENESIS, TYPE IA; ACG1A  TRIP11
TUBEROUS SCLEROSIS 1; TSC1  TSC1
NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX  WAS
WISKOTT-ALDRICH SYNDROME; WAS  WAS
WERNER SYNDROME; WRN  WRN
FRASIER SYNDROME  WT1
DENYS-DRASH SYNDROME; DDS  WT1


Please add your favorite if you see that I have missed something.

No comments:

Post a Comment